| human | Q5 |
| P496 | ORCID iD | 0000-0003-0894-4009 |
| P69 | educated at | University of Buenos Aires | Q194223 |
| University of Maryland School of Medicine | Q17681492 | ||
| P108 | employer | University of Maryland School of Medicine | Q17681492 |
| P734 | family name | Pasetti | Q25114971 |
| Pasetti | Q25114971 | ||
| Pasetti | Q25114971 | ||
| P735 | given name | Marcela | Q19798827 |
| Marcela | Q19798827 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q91760327 | A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice |
| Q57929967 | A Novel Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge |
| Q90621575 | A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization |
| Q33801151 | A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection |
| Q39015820 | A bivalent typhoid live vector vaccine expressing both chromosome- and plasmid-encoded Yersinia pestis antigens fully protects against murine lethal pulmonary plague infection |
| Q39464862 | A clinical study to assess the safety and immunogenicity of attenuated measles vaccine administered intranasally to healthy adults |
| Q33557714 | A new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectors |
| Q50044950 | A novel Salmonella Typhi-based immunotherapy promotes tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model of breast cancer |
| Q37721649 | A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions. |
| Q41986831 | A randomized, placebo-controlled, double-blind Phase 2 trial comparing the reactogenicity and immunogenicity of a single ≥2x108 colony forming units [cfu] standard-dose versus a ≥2x109 cfu high-dose of CVD 103-HgR live attenuated oral cholera vaccin |
| Q42915324 | A scalable method for biochemical purification of Salmonella flagellin |
| Q46339112 | A serosurvey to identify the window of vulnerability to wild-type measles among infants in rural Mali |
| Q28277086 | ASM Journals Eliminate Impact Factor Information from Journal Websites |
| Q42334083 | ASM Journals Eliminate Impact Factor Information from Journal Websites |
| Q59511842 | ASM Journals Eliminate Impact Factor Information from Journal Websites |
| Q59511844 | ASM Journals Eliminate Impact Factor Information from Journal Websites |
| Q59511852 | ASM Journals Eliminate Impact Factor Information from Journal Websites |
| Q59511857 | ASM Journals Eliminate Impact Factor Information from Journal Websites |
| Q59511861 | ASM Journals Eliminate Impact Factor Information from Journal Websites |
| Q59511870 | ASM Journals Eliminate Impact Factor Information from Journal Websites |
| Q42336943 | ASM Journals Eliminate Impact Factor Information from Journal Websites. |
| Q94052041 | Acknowledgment of Reviewers |
| Q94392385 | Acknowledgment of Reviewers |
| Q94411492 | Acknowledgment of Reviewers |
| Q45822664 | Acknowledgment of Ad Hoc Reviewers |
| Q37623663 | Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA. |
| Q103796957 | Adjustments for oral fluid quality and collection methods improve prediction of circulating tetanus antitoxin: Approaches for correcting antibody concentrations detected in a non-invasive specimen |
| Q37044185 | Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues |
| Q37483766 | Age-dependent association among Helicobacter pylori infection, serum pepsinogen levels and immune response of children to live oral cholera vaccine CVD 103-HgR |
| Q34433313 | An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor. |
| Q37183341 | An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes |
| Q35047221 | Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors |
| Q34761957 | Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine |
| Q35065640 | Assessment of the epidemiology and burden of measles in Southern Mozambique |
| Q34976024 | Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats |
| Q40163181 | Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products |
| Q35805439 | Broadly protective Shigella vaccine based on type III secretion apparatus proteins |
| Q34070619 | Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella Paratyphi A vaccines |
| Q40577238 | Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine |
| Q38776163 | Characterization of a multicomponent live, attenuated Shigella flexneri vaccine |
| Q33908929 | Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins |
| Q30414497 | Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain |
| Q36844719 | Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road |
| Q34557946 | Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. |
| Q60043981 | Completion of an Experiment |
| Q40565111 | Concomitant induction of CD4+ and CD8+ T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA. |
| Q91801450 | Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays |
| Q38737485 | Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity. |
| Q39146446 | Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. |
| Q58762161 | Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa |
| Q92726819 | Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis |
| Q55333715 | Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Shigella Serum Bactericidal Assay. |
| Q35273267 | Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains |
| Q35949699 | Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy |
| Q45071462 | Enterotoxigenic Escherichia coli is phagocytosed by macrophages underlying villus-like intestinal epithelial cells: modeling ex vivo innate immune defenses of the human gut. |
| Q33630881 | Erratum: A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions |
| Q59134868 | Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG |
| Q96639167 | Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies |
| Q37032264 | Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. |
| Q35964671 | Functional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal Salmonella |
| Q37633069 | Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study |
| Q91741853 | Functional antibodies as immunological endpoints to evaluate protective immunity against Shigella |
| Q34068059 | Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans |
| Q47701344 | Haemophilus influenzae Type B conjugate vaccine introduction in Mali: impact on disease burden and serologic correlate of protection. |
| Q37696600 | Helicobacter pylori infection affects immune responses following vaccination of typhoid-naive U.S. adults with attenuated Salmonella typhi oral vaccine CVD 908-htrA. |
| Q42554197 | Highlights of the 8th International Conference on Vaccines for Enteric Diseases: the Scottish Encounter To Defeat Diarrheal Diseases |
| Q40192692 | Human immune responses against Shigella and enterotoxigenic E. coli: Current advances and the path forward |
| Q40530217 | Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide |
| Q35943000 | Immunization Coverage Surveys and Linked Biomarker Serosurveys in Three Regions in Ethiopia |
| Q54201279 | Immunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in infant and adult mice. |
| Q80842328 | Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn |
| Q91700936 | Improved Tolerability of a Salmonella enterica Serovar Typhimurium Live-Attenuated Vaccine Strain Achieved by Balancing Inflammatory Potential with Immunogenicity |
| Q59806094 | Improving Our Understanding of Serovar Paratyphi B through the Engineering and Testing of a Live Attenuated Vaccine Strain |
| Q41426133 | Insights from natural infection-derived immunity to cholera instruct vaccine efforts |
| Q37720658 | Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes |
| Q45356767 | Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. |
| Q36806619 | Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses |
| Q37429384 | Live Attenuated Human Salmonella Vaccine Candidates: Tracking the Pathogen in Natural Infection and Stimulation of Host Immunity |
| Q37643333 | Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B |
| Q90290863 | Maternal Antibodies Elicited by Immunization With an O- Polysaccharide Glycoconjugate Vaccine Protect Infant Mice Against Lethal Salmonella Typhimurium Infection |
| Q89946334 | Maternal determinants of infant immunity: Implications for effective immunization and maternal-child health |
| Q37176794 | Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial |
| Q62486723 | Measles-specific neutralizing antibodies in rural Mozambique: seroprevalence and presence in breast milk |
| Q80186096 | Measurement of tetanus antitoxin in oral fluid: a tool to conduct serosurveys |
| Q41941037 | Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. |
| Q28387065 | Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine |
| Q34121874 | Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies |
| Q36444097 | Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers |
| Q33824782 | Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost |
| Q36005810 | Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in Mali |
| Q40290632 | Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies |
| Q40734790 | Opsonophagocytic Assay To Evaluate Immunogenicity of Nontyphoidal Salmonella Vaccines |
| Q34562262 | Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans |
| Q98244729 | Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases |
| Q100512321 | Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults |
| Q45394779 | Preclinical safety and biodistribution of Sindbis virus measles DNA vaccines administered as a single dose or followed by live attenuated measles vaccine in a heterologous prime-boost regimen |
| Q92308204 | Pregnancy level of estradiol attenuated virus-specific humoral immune response in H5N1-infected female mice despite inducing anti-inflammatory protection |
| Q37105553 | Progress and pitfalls in Shigella vaccine research |
| Q95940540 | RSV neutralizing antibodies at birth predict protection from RSV illness in infants in the first three months of life |
| Q50097465 | Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy |
| Q36281257 | Refined live attenuated Salmonella enterica serovar Typhimurium and Enteritidis vaccines mediate homologous and heterologous serogroup protection in mice |
| Q37477201 | Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax. |
| Q46607652 | Safety and Immunogenicity of a Single Oral Dose of Recombinant Double Mutant Heat-Labile Toxin Derived from Enterotoxigenic Escherichia coli. |
| Q81445405 | Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media |
| Q40160745 | Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study |
| Q91010881 | Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study |
| Q37335500 | Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli |
| Q122678001 | Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial |
| Q64376875 | Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial |
| Q37544964 | Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. |
| Q42264370 | Safety and tolerability of a live oral Salmonella typhimurium vaccine candidate in SIV-infected nonhuman primates |
| Q43536234 | Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector |
| Q37430026 | Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and meta-analysis |
| Q34127550 | Salmonella enterica serovar Typhi live vector vaccines delivered intranasally elicit regional and systemic specific CD8+ major histocompatibility class I-restricted cytotoxic T lymphocytes |
| Q37106127 | Salmonella enterica serovar Typhi live vector vaccines finally come of age |
| Q35272921 | Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis |
| Q37067246 | Serological Monitoring Is Key To Sustain Progress of the Maternal and Neonatal Tetanus Elimination Initiative |
| Q33601858 | Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines |
| Q35946462 | Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice. |
| Q40905058 | Simple method for purification of enterotoxigenic Escherichia coli fimbriae |
| Q37110690 | Sindbis virus-based measles DNA vaccines protect cotton rats against respiratory measles: relevance of antibodies, mucosal and systemic antibody-secreting cells, memory B cells, and Th1-type cytokines as correlates of immunity |
| Q36915108 | Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. |
| Q42918016 | Springtime for CVI. |
| Q35934056 | Strategies for Coordination of a Serosurvey in Parallel with an Immunization Coverage Survey. |
| Q34760675 | Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates. |
| Q47131889 | The Legacy of CVI. |
| Q94475184 | The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route |
| Q39179709 | Therapeutic effects of Salmonella typhi in a mouse model of T-cell lymphoma |
| Q34025527 | Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy |
| Q50105781 | Towards new immunotherapies: targeting recombinant cytokines to the immune system using live attenuated Salmonella |
| Q38373222 | Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial |
| Q87747419 | Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results |
| Q89239276 | WITHDRAWN: Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG |
| Q64981497 | mSphere of Influence: the View from the Microbiologists of the Future. |
Search more.